---
document_datetime: 2023-12-08 10:56:11
document_pages: 17
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/toviaz-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: toviaz-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 11.4823621
conversion_datetime: 2025-12-28 15:13:25.44134
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Toviaz

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IA/0069/G            | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test | 20/11/2023                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0068 | Update of section 4.4 of the SmPC to amend an existing warning on angioedema and 4.8 of the SmPC in order to add hypoaesthesia oral to the list of adverse drug reactions (ADRs) with a frequency rare based on a cumulative review of safety database cases and literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the QRD template v10.3. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 19/10/2023 |            | SmPC and PL           | Based on cumulative reviews, the warning in section 4.4 of SmPC on angioedema has been updated to reflect that 'some cases may be associated with upper airway swelling and may be life-threatening'. In addition, hypoaesthesia oral had been added in section 4.8 of SmPC with a frequency 'rare'. For more information, please refer to the Summary of Product Characteristics.                                                                                                                                                       |
| IA/0067 | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 10/01/2023 | 15/09/2023 | Annex II and PL       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0063 | C.I.3 Update of sections 4.2, 5.1 and 5.2 of the SmPC with the results from study A0221047, to evaluate the safety and efficacy of fesoterodine in subjects aged 6 to 17 years with neurogenic detrusor overactivity. The change was suggested in the outcome of the EMEA/H/C/000723/P46/030.1. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet                                                                                  | 06/10/2022 | 15/09/2023 | SmPC, Annex II and PL | This variation concerned the submission of data from Study A0221047, a phase 3, randomized, open-label study to evaluate the safety and efficacy of fesoterodine on paediatric patients aged 6 to 17 with symptoms of detrusor overactivity associated with Neurogenic Detrusor Overactivity (NDO). Treatment with fesoterodine 4 mg or 8 mg tablets resulted in improvements from baseline in maximum cystometric bladder capacity (MCBC) at Week 12 for paediatric patients > 25 kg, with numerically higher changes from baseline for |

<div style=\"page-break-after: always\"></div>

|           | and to bring the PI in line with the latest QRD template version 10.1. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH                                                                                                                                                                                                                                                                                                  |            |     | fesoterodine 8 mg tablets than for fesoterodine 4 mg tablets. Overall, the safety profile in paediatric patients with neurogenic detrusor overactivity was similar to that observed in adults with overactive bladder syndrome. These safety and efficacy data from Study A0221047 have been described in section 5.1 and 5.2. of the SmPC. No recommendation on posology can be made and uncertainties on the long-term safety remain. Overall, data from this study, although considered positive, remain limited. The safety and efficacy of Toviaz in children aged less than 6 years has not been established. For more information, please refer to the Summary of Product Characteristics.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0066   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 30/08/2022 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0065/G | This was an application for a group of variations. B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) | 03/03/2022 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| B.II.c.1.c - Change in the and/or limits of an excipient significant specification an obsolete parameter) B.II.c.1.c - Change in the and/or limits of an excipient significant specification an obsolete parameter) B.II.c.1.c - Change in the and/or limits of an excipient significant specification an obsolete parameter) B.II.c.1.c - Change in the and/or limits of an excipient significant specification an obsolete parameter) B.II.d.1.f - Change in the and/or limits of the finished specification parameter effect on the overall quality B.II.c.2.a - Change in test - Minor changes to an B.II.b.5.e - Change to applied during the manufacture product - Widening of the may have a significant finished product B.II.b.3.b - Change in the finished or intermediate changes to a manufacturing significant impact on the   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         | B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change requires assessment of the comparability of a biological/immunological medicinal product or a new bioequivalence study B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.a.2.b - Change in the shape or dimensions of the pharmaceutical form - Gastro-resistant, modified or prolonged release pharmaceutical forms and scored tablets intended to be divided into equal doses A.7 - Administrative change - Deletion of   |            |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0062 | Submission of an updated RMP version 10.0 in order to align the important identified risks, important potential risks, and missing information with the new Guideline on good pharmacovigilance practice (GVP) Module V - Risk management systems (Revision 2.0), and to address the PSUR PRAC recommendation (EMEA/H/C/PSUSA/00001387/202004). RMP Version 10.0 is accepted.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 28/10/2021 | n/a | The current variation involved revision of the list of safety concerns of the Risk Management Plan (RMP) according to the current Guideline on good pharmacovigilance practice (GVP) Module V - Risk management systems (Revision 2.0) and the outcome of the last PSUR PRAC recommendation (EMEA/H/C/PSUSA/00001387/202004). The important identified risks (Urinary retention, Angioedema), important potential risks (QT prolongation, Hepatotoxicity, Cognitive function impairment) and missing information (Elderly male patients, Paediatric patients, Pregnant or nursing women) |

<div style=\"page-break-after: always\"></div>

|                    | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   |            |            |           | were removed from RMP since no additional risk minimisation measures nor additional pharmacovigilance activities are proposed.   |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------|----------------------------------------------------------------------------------------------------------------------------------|
| N/0064             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                 | 01/10/2021 | 15/09/2023 | PL        |                                                                                                                                  |
| N/0060             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                 | 27/11/2020 | 15/09/2023 | PL        |                                                                                                                                  |
| PSUSA/1387/ 202004 | Periodic Safety Update EU Single assessment - fesoterodine, desfesoterodine                                                                                                                                                                                                                      | 26/11/2020 | n/a        |           | PRAC Recommendation - maintenance                                                                                                |
| IA/0059            | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                     | 22/11/2020 | n/a        |           |                                                                                                                                  |
| N/0057             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                 | 13/11/2019 | 16/07/2020 | PL        |                                                                                                                                  |
| N/0056             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                 | 05/09/2019 | 16/07/2020 | Labelling |                                                                                                                                  |
| IAIN/0055          | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                               | 29/07/2019 | n/a        |           |                                                                                                                                  |
| IB/0054/G          | This was an application for a group of variations.                                                                                                                                                                                                                                               | 22/07/2019 | 16/07/2020 | SmPC,     |                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|         | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure   |            |            | Labelling and PL       | (including   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------|
| IA/0053 | B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 19/12/2018 | n/a        |                        |              |
| T/0052  | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 11/07/2018 | 30/07/2018 | SmPC, Labelling and PL |              |

<div style=\"page-break-after: always\"></div>

| IB/0051            | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                         | 22/03/2018   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1387/ 201704 | Periodic Safety Update EU Single assessment - fesoterodine, desfesoterodine                                                                                                                                                                                                                                              | 30/11/2017   | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0049            | Update of the SmPC sections 4.6 and 5.3 with revised information from reproductive toxicity studies in mice. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.0. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 14/09/2017   | 30/07/2018 | SmPC and Labelling    | In this variation the MAH has revised the product information to reflect that a study of fertility and early embryonic development in mice, showed some findings, namely a lower number of corpora lutea, implantation sites, and viable foetuses in females administered fesoterodine at 45 mg/kg/day for 2 weeks prior to mating and continuing through day 7 of gestation. Findings in mice corresponded to exposures approximately 5 to 19 times those at the maximum recommended human dose (MRHD) on female fertility and 6 times those at MRHD on fetotoxicity, however, the clinical implications of these animal findings |
| IA/0048            | B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier                                                                                                                                                                                              | 18/10/2016   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IB/0047            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                           | 03/08/2016   | 06/07/2017 | SmPC, Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| N/0046             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                         | 24/06/2015   | 23/09/2015 | PL                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUV/0042          | Periodic Safety Update                                                                                                                                                                                                                                                                                                   | 06/11/2014   | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| IAIN/0045   | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                               | 23/10/2014   | 23/09/2015   | Annex II and PL        |                                                                                                                                          |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0044     | B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier                                                                                                                                                                              | 25/09/2014   | n/a          |                        |                                                                                                                                          |
| IA/0043     | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                             | 21/08/2014   | n/a          |                        |                                                                                                                                          |
| IB/0041     | B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                           | 01/07/2013   | n/a          |                        |                                                                                                                                          |
| IG/0235/G   | This was an application for a group of variations. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV                         | 06/12/2012   | n/a          |                        | C.I.z - To replace the Detailed Description of the Pharmacovigilance System (DDPS) with the Pharmacovigilance System Master File (PSMF). |
| IAIN/0039/G | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished | 28/09/2012   | 25/10/2012   | SmPC, Labelling and PL |                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|           | product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes                                                                                                                                                                                                                                                                                                                         |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0169/G | This was an application for a group of variations. C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of | 08/06/2012 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| R/0034    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                 | 19/01/2012 | 15/03/2012 |             | Based on the review of the available information the CHMP is of the opinion that the quality, the safety and the efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considers that the benefit/risk profile of Toviaz continues to be favorable. The CHMP was of the opinion that the renewal could be granted with unlimited validity. However the MAH will continue to submit yearly PSURs, unless otherwise specified by the CHMP. |
| II/0033   | Update of Summary of Product Characteristics and Package Leaflet. Changes to section 4.4 of the SmPC to include a warning regarding the risk of angioedema. The Package Leaflet has been updated accordingly.                                                                                                                                                                                                                                                           | 22/09/2011 | 24/10/2011 | SmPC and PL | Review of the available data from the clinical trials and post-marketing reports, conducted by the MAH, concluded that cases of angioedema have been reported, in some cases shortly after initiation of the treatment with fesoterodine. Since angioedema can cause potentially                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|         | C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |             | serious medical consequences the MAH proposed to include a warning to stop the treatment with fesoterodine in case an angioedema develops. This was endorsed by the CHMP.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0035 | A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 27/09/2011 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0029 | Update to sections 4.2, 4.5 and 4.8 of the SmPC with safety data regarding confusional state, palpitations, blurred vision and angioedema, as well as clinical study results for a study evaluating the effect of fluconazole on fesoterodine, in accordance with the request from the CHMP following the assessment of PSUR 5. Sections 2 and 4 of the PIL were updated accordingly. Additionally, the MAH took this oportunity to make some editorial amendments in sections 4.5 and 10 of the SmPC and section 6 of the PIL. Finally, the data presentation in section 4.8 of the SmPC has been revised in line with the Guideline on the Summary of Product Characteristics. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH | 17/02/2011 | 24/03/2011 | SmPC and PL | Results of study A0221080, which evaluated the effect of fluconazole, a moderate CYP3A4 inhibitor, on the single- dose pharmacokinetics of fesoterodine in healthy subjects, showed that co-administration of fesoterodine 8 mg with fluconazole 200 mg BID increased the Cmax and AUCinf of 5-HMT by approximately 19% and 27%, respectively. Section 4.5 of the SmPC was updated to reflect this information, and a related change was introduced in SmPC section 4.2 regarding the concomitant administration of moderate CYP3A4 inhibitors. Additionally, further to reports included in the 5th PSUR (covering the period 20.04.09 - 19.10.09), the following undesirable effects were included in section 4.8 of the SmPC: palpitations (uncommon), blurred vision (uncommon), angioedema (rare) and confusional state (rare). |

<div style=\"page-break-after: always\"></div>

| IG/0044/G   | This was an application for a group of variations. C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system   | 02/03/2011   | n/a        | Annex II              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0032     | C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                              | 14/01/2011   | n/a        | SmPC, Annex II and PL | Implementation of changes to Section 4.8 to add \"pruritus\" and \"urticaria\" as adverse events reported post-marketing as requested in PSUR 6 AR. The MAH also takes the opportunity to update the PIL with an administrative change for the Icelandic local representative and to make other editorial changes in some of the EU language translations.                                                                                                                                |
| II/0031     | C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 23/09/2010   | 25/10/2010 | SmPC                  | The MAH has proposed change to section 4.5 of the SmPC with information on interaction with warfarin from a clinical study in healthy volunteers to evaluate the steady-state effect of fesoterodine (8 mg once daily) on the PK and PD of a single dose of warfarin (25 mg). From this study it was concluded that their was a lack of interactive PK effect or interactive PD effect when warfarin is co-administered with fesoterodine. These results are in line with theoretical |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |             | considerations concerning warfarin metabolism, as well as the conclusion from the review of the safety database. The update of section 4.5 of the SmPC is acceptable and does not affect the overall positive benefit-risk balance of this product.                                                                                                                                                                                                                                                                                                                    |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0030/G | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test | 25/06/2010 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0025   | Update to sections 4.4 and 4.8 of SmPC with information on urinary retention as well as gastroesophageal reflux. The Package Leaflet was updated accordingly in sections 2 and 4. This update was made further to the request of the CHMP following assessment of 4th PSUR (period 20.10.2008 - 19.04.2009). Update of Summary of Product Characteristics and Package Leaflet                                                                                                                | 22/04/2010 | 04/06/2010 | SmPC and PL | The MAH has reviewed the safety data from eight double- blind, placebo-controlled fesoterodine clinical trials, which included 2,349 subjects that received placebo and 3,791 subjects that received fesoterodine, from four open-label studies and from the MAH's safety database (from 20 April 2007 through 19 October 2009) . The incidence rate for urinary retention in the pooled double-blind trials was observed to be 0.7% for fesoteridine and 0.1% for placebo. Taking also into account the open label studies, the pooled incidence rate in fesoteridine |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                               |            |            | treated patients in clinical trials is 0.9%. The search of the safety database confirmed 38 cases of urinary retention considered as serious (i.e. associated with catherisation and/or hospitalization). Many of these cases were reported in elderly male patients, who had a history consistent with benign prostatic hyperplasia. It is therefore considered appropriate to indicate 'clinically significant prostate enlargement due to benign prostatic hyperplasia' as an example of a condition with clinically significant bladder outflow obstruction at risk of urinary retention. Additionally, it was also concluded from the same pooled data, that gastroesophageal reflux, whose incidence rate was observed to be 0.4%, should be added as an adverse drug reaction. The search in the safety database confirmed 4 cases where 3 of the 4 cases provided very little information. The remaining case involved a 70-year-old male patient who experienced acid reflux during the first week of starting fesoterodine 8 mg daily. The frequency of   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0027 | To add Near Infrared Spectroscopy (NIR) as an alternate method for water content determination in the finished product B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) | 04/03/2010 | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0024 | Addition of alternative manufacturing process for an intermediate in the synthesis of fesoterodine fumarate and addition of an alternate test side.                                                                                                           | 17/12/2009 | 06/01/2010 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|         | to the manufacturing process for the substance                                                                                                                                                                                                                                  |            |            |                        | Change(s) active   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------|
| II/0021 | Update of DDPS (Pharmacovigilance)                                                                                                                                                                                                                                              | 25/06/2009 | 29/07/2009 | Annex II               |                    |
| IB/0023 | IB_41_a_02_Change in pack size - change in no. of units outside range of appr. pack size                                                                                                                                                                                        | 08/07/2009 | 08/07/2009 | SmPC, Labelling and PL |                    |
| IB/0022 | IB_41_a_02_Change in pack size - change in no. of units outside range of appr. pack size                                                                                                                                                                                        | 08/07/2009 | 08/07/2009 | SmPC, Labelling and PL |                    |
| N/0019  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                | 25/02/2009 | n/a        | PL                     |                    |
| IA/0020 | IA_36_ b_Change in shape or dimensions of the container/closure - other pharm. forms                                                                                                                                                                                            | 04/02/2009 | n/a        |                        |                    |
| II/0017 | Update of the Detailed Description of the Pharmacovigilance system (DDPS) version 1.1. Update of DDPS (Pharmacovigilance)                                                                                                                                                       | 23/10/2008 | 28/11/2008 | Annex II               |                    |
| II/0016 | The applicant has applied to add 50 cc and 100 cc white opaque High-Density Polyethylene Bottles as an alternate primary packaging for Toviaz 4 mg and 8 mg prolonged release tablets. The new pack sizes to be included are 30 tablets (50 cc bottle) and 90 tablets (100 cc). | 23/10/2008 | 28/11/2008 | SmPC, Labelling and PL |                    |

<div style=\"page-break-after: always\"></div>

|         | New presentation(s)                                                                                                                                                                                                               |            |            |                        |                  |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------|
| II/0015 | The MAH applied for the addition an alternative manufacturer for the active substance. In this context, the MAH introduced minor changes to the manufacturing process. Update of or change(s) to the pharmaceutical documentation | 23/10/2008 | 28/10/2008 |                        |                  |
| IA/0018 | IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                                                                                                 | 09/09/2008 | n/a        | Annex II and PL        |                  |
| II/0014 | Change(s) to shelf-life or storage conditions                                                                                                                                                                                     | 30/05/2008 | 07/07/2008 | SmPC, Labelling and PL |                  |
| N/0012  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                  | 08/05/2008 | n/a        | Labelling and PL       |                  |
| II/0009 | Change(s) to the manufacturing process for the                                                                                                                                                                                    | 19/03/2008 | 31/03/2008 |                        | active substance |
| II/0008 | Change(s) to the manufacturing process for the active substance                                                                                                                                                                   | 19/03/2008 | 31/03/2008 |                        |                  |
| IA/0011 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size                                                                                                                                           | 01/02/2008 | 01/02/2008 | SmPC, Labelling and PL |                  |
| IA/0010 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size                                                                                                                                           | 01/02/2008 | 01/02/2008 | SmPC, Labelling and    |                  |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                  |            |            | PL                     |
|---------|--------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| IA/0007 | IA_08_b_02_Change in BR/QC testing - repl./add. manuf. responsible for BR - incl. BC/testing     | 18/12/2007 | n/a        | Annex II and PL        |
| IA/0005 | IA_39_Change/addition of imprints, bossing or other markings                                     | 18/12/2007 | n/a        | SmPC and PL            |
| IA/0006 | IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms          | 14/12/2007 | n/a        |                        |
| IB/0002 | IB_12_b_01_Change in spec. of active subst./agent in manuf. of active subst. - test parameter AS | 29/11/2007 | n/a        |                        |
| IB/0004 | IB_12_b_01_Change in spec. of active subst./agent in manuf. of active subst. - test parameter AS | 16/10/2007 | n/a        |                        |
| IB/0003 | IB_12_b_01_Change in spec. of active subst./agent in manuf. of active subst. - test parameter AS | 16/10/2007 | n/a        |                        |
| T/0001  | Transfer of Marketing Authorisation                                                              | 08/08/2007 | 18/09/2007 | SmPC, Labelling and PL |